AR124310A1 - INMUNOCITOQUINA PARA ACTIVAR EL RECEPTOR IL-10Ra HUMANO Y SU USO - Google Patents

INMUNOCITOQUINA PARA ACTIVAR EL RECEPTOR IL-10Ra HUMANO Y SU USO

Info

Publication number
AR124310A1
AR124310A1 ARP210103441A ARP210103441A AR124310A1 AR 124310 A1 AR124310 A1 AR 124310A1 AR P210103441 A ARP210103441 A AR P210103441A AR P210103441 A ARP210103441 A AR P210103441A AR 124310 A1 AR124310 A1 AR 124310A1
Authority
AR
Argentina
Prior art keywords
immunocytokine
human
receptor
methods
pharmaceutical compositions
Prior art date
Application number
ARP210103441A
Other languages
English (en)
Inventor
Aleksey Vladimirovich Kononov
Iuliia Viktorovna Evdokimovskaia
Iana Andreevna Smirnova
Stanislav Rudolfovich Evdokimov
Elena Sergeevna Kolosova
Sergei Andreevich Ageev
Vladimir Sergeevich Tsympilov
Valery Vladimirovich Solovyev
Pavel Andreevich Iakovlev
Dmitry Valentinovich Morozov
Original Assignee
Joint Stock Company “Biocad”
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from RU2020140807A external-priority patent/RU2810750C2/ru
Application filed by Joint Stock Company “Biocad” filed Critical Joint Stock Company “Biocad”
Publication of AR124310A1 publication Critical patent/AR124310A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5428—IL-10
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2066—IL-10
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La presente invención se refiere al campo de la biotecnología y la medicina, en particular a una inmunocitoquina para activar el receptor IL-10Ra humano. La invención se refiere además a ácidos nucleicos que codifican dicha inmunocitoquina, vectores de expresión, células huésped y métodos para producirlos, métodos para producir la inmunocitoquina, composiciones farmacéuticas que comprenden la inmunocitoquina mencionada, composiciones farmacéuticas que comprenden la inmunocitoquina mencionada y otros compuestos terapéuticamente activos, métodos para tratar una enfermedad oncológica y los usos de la inmunocitoquina o de las composiciones farmacéuticas de la misma para tratar una enfermedad oncológica. Reivindicación 1: Una inmunocitoquina aislada para activar el receptor IL-10Ra humano, que comprende un complejo homodimérico basado en IL-10 y fragmento Fc de IgG1 humana, en el que el monómero basado en IL-10 y fragmento Fc de IgG1 humana comprende la secuencia de aminoácidos de SEQ ID Nº 1.
ARP210103441A 2020-12-10 2021-12-10 INMUNOCITOQUINA PARA ACTIVAR EL RECEPTOR IL-10Ra HUMANO Y SU USO AR124310A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
RU2020140807A RU2810750C2 (ru) 2020-12-10 Иммуноцитокин для активации IL-10Rα рецептора человека и его применение

Publications (1)

Publication Number Publication Date
AR124310A1 true AR124310A1 (es) 2023-03-15

Family

ID=81973601

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP210103441A AR124310A1 (es) 2020-12-10 2021-12-10 INMUNOCITOQUINA PARA ACTIVAR EL RECEPTOR IL-10Ra HUMANO Y SU USO

Country Status (19)

Country Link
US (1) US20240034764A1 (es)
EP (1) EP4259644A1 (es)
JP (1) JP2023553934A (es)
KR (1) KR20230118919A (es)
CN (1) CN117120461A (es)
AR (1) AR124310A1 (es)
AU (1) AU2021398529A1 (es)
CA (1) CA3201656A1 (es)
CL (1) CL2023001677A1 (es)
CO (1) CO2023007563A2 (es)
CR (1) CR20230243A (es)
EC (1) ECSP23043458A (es)
IL (1) IL303501A (es)
MA (1) MA61003A1 (es)
MX (1) MX2023006830A (es)
PE (1) PE20241070A1 (es)
TW (1) TW202237631A (es)
UY (1) UY39562A (es)
WO (1) WO2022124950A1 (es)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20150645A1 (es) * 2012-08-08 2015-05-11 Roche Glycart Ag Proteinas de fusion de interleuquina 10 y usos de las mismas
MX2016010174A (es) * 2014-02-06 2016-11-15 Hoffmann La Roche Proteinas de fusion de interleucina-10 y usos de las mismas.

Also Published As

Publication number Publication date
JP2023553934A (ja) 2023-12-26
UY39562A (es) 2022-05-31
CA3201656A1 (en) 2022-06-16
CN117120461A (zh) 2023-11-24
PE20241070A1 (es) 2024-05-13
IL303501A (en) 2023-08-01
MA61003A1 (fr) 2023-10-31
EP4259644A1 (en) 2023-10-18
TW202237631A (zh) 2022-10-01
US20240034764A1 (en) 2024-02-01
AU2021398529A1 (en) 2023-06-29
CL2023001677A1 (es) 2024-01-19
CO2023007563A2 (es) 2023-07-21
MX2023006830A (es) 2023-07-06
CR20230243A (es) 2023-07-13
WO2022124950A1 (en) 2022-06-16
ECSP23043458A (es) 2023-07-31
KR20230118919A (ko) 2023-08-14

Similar Documents

Publication Publication Date Title
DE69735376T2 (de) Fusionsproteine, die stressproteine beinhalten, zum hervorrufen einer immunantwort
Wangkahart et al. Re-examination of the rainbow trout (Oncorhynchus mykiss) immune response to flagellin: Yersinia ruckeri flagellin is a potent activator of acute phase proteins, anti-microbial peptides and pro-inflammatory cytokines in vitro
JPH08508252A (ja) 小胞体シグナル配列ペプチドと少なくとも１個の他のペプチドをエンコードする核酸配列を含有する免疫原性キメラ、及びこのキメラのワクチン及び疾患の治療における使用
BRPI0412799A (pt) imunógeno, composição, ácido nucleico, célula recombinante, métodos para preparar um polipeptìdeo, para induzir um a resposta imune protetora em um paciente e para induzir uma resposta anamnésica em um paciente, e, seqüência de ácido nucleico otimizada de levedura
BRPI0815578B8 (pt) Peptídeo de cdca1, seu uso e composição imunogênica compreendendo o mesmo para induzir imunidade, tratar e/ou prevenir o câncer, bem como método in vitro para induzir uma célula apresentadora de antígeno e uma célula t citotóxica (killer)
AR079114A1 (es) Proteinas de enlace de antigenos anti-orai1 y usos de las mismas
CA3136691A1 (en) Recombinant elastin and production thereof
JP2017511133A5 (es)
CL2023001434A1 (es) Muteína de il-2; proteína de fusión; ácido nucleico; vector; célula hospedera; métodos; uso
PE20231439A1 (es) Proteinas f de hmpv estabilizadas por prefusion
JP2021509254A (ja) Ｈ３ｎ２亜型インフルエンザウイルスのヘマグルチニンタンパク質の突然変異体及びその使用
AR035077A1 (es) Polipeptidos de neublastina variante, proteinas de fusion, acidos nucleicos, vectores, celulas hospedadoras, metodos para producir dichos polipeptidos, dimeros, conjugados, composiciones farmaceuticas y uso de dichos polipeptidos en la preparacion de medicamentos
EP1492814B1 (fr) Peptide dérivé de l'interleukine-1-beta et son application thérapeutique
Tinker et al. Immunogenicity of a West Nile virus DIII-cholera toxin A2/B chimera after intranasal delivery
AR041086A1 (es) Vacuna
AR124310A1 (es) INMUNOCITOQUINA PARA ACTIVAR EL RECEPTOR IL-10Ra HUMANO Y SU USO
AR123628A1 (es) Constructos anti-cd93 y usos de estos
Liu et al. Gene cloning, expression and vaccine testing of Schistosoma japonicum SjFABP
Luke et al. Thermostable tag (TST) protein expression system: Engineering thermotolerant recombinant proteins and vaccines
AR029168A1 (es) Una composicion acidos nucleicos peptidicos y un metodo para prepararla
Tao et al. Th1-type epitopes-based cocktail PDDV attenuates hepatic fibrosis in C57BL/6 mice with chronic Schistosoma japonicum infection
Lacasta et al. Design and immunological evaluation of two-component protein nanoparticle vaccines for East Coast fever
CL2023001072A1 (es) Ácido nucleico que codifica una entidad anti-vegf y un regulador del complemento negativo; usos
AR045671A1 (es) Moleculas de union de nogo a y su uso farmaceutico
KR20210065086A (ko) 자가-조립형 펩타이드 스캐폴드